TBPH Q1 2022 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M-7.4% YoY

Gross Profit

-$10M-76.2% margin

Operating Income

-$37M-282.1% margin

Net Income

-$26M-196.6% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-11.7%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$355M

Total Liabilities

$707M

Stockholders' Equity

-$351M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$14M	-7.4%
Gross Profit	-$10M	-$53M	+81.1%
Operating Income	-$37M	-$84M	+55.6%
Net Income	-$26M	-$80M	+67.4%

Revenue Segments

YUPELRI Monotherapy

$15M54%

Viatris collaboration agreement

$11M38%

Licensing revenue

$3M9%

Collaborative revenue

$9,0000%